Financial Instruments and Fair Value Measurements (Tables)

6 Months Ended

Mar. 27, 2015

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:

	March 27, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	36.8	$	25.0	$	11.8	$	—
Foreign exchange forward and option contracts	0.3		0.3		—		—
	$	37.1	$	25.3	$	11.8	$	—
Liabilities:
Deferred compensation liabilities	$	19.1	$	—	$	19.1	$	—
Contingent consideration and acquired contingent liabilities	198.2		—		—		198.2
Foreign exchange forward and option contracts	5.4		5.4		—		—
	$	222.7	$	5.4	$	19.1	$	198.2

	September 26, 2014		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.7	$	22.9	$	12.8	$	—
	$	35.7	$	22.9	$	12.8	$	—
Liabilities:
Deferred compensation liabilities	$	15.0	$	—	$	15.0	$	—
Contingent consideration and acquired contingent liabilities	202.8		—		—		202.8
Foreign exchange forward and option contracts	0.2		0.2		—		—
	$	218.0	$	0.2	$	15.0	$	202.8

Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities

Balance at September 26, 2014	$	202.8
Payments	(4.0		)
Accretion expense	4.1
Effect of currency rate change	(4.7		)
Balance at March 27, 2015	$	198.2

Schedule of Carrying Amount and Fair Value of Long-term Debt

The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:

	March 27, 2015				September 26, 2014
	Carrying Value		Fair Value		Carrying Value		Fair Value
Variable-rate receivable securitization	$	180.0	$	180.0	$	150.0	$	150.0
2.85% term loan due April 2016	2.6		2.6		3.1		3.1
3.50% notes due April 2018	300.0		296.2		300.0		290.2
Term loans due March 2021	1,982.7		1,985.2		1,990.3		1,970.4
4.00% term loan due February 2022	9.0		9.0		10.8		10.8
9.50% debentures due May 2022	10.4		13.2		10.4		14.2
5.75% notes due August 2022	900.0		927.3		900.0		907.3
8.00% debentures due March 2023	4.7		5.5		8.0		10.2
4.75% notes due April 2023	598.4		572.3		598.3		563.8

Schedules of Concentration of Risk

The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales:

	Three Months Ended				Six Months Ended
	March 27, 2015		March 28, 2014		March 27, 2015		March 28, 2014
CuraScript, Inc.	25	%	—	%	28	%	—	%
McKesson Corporation	19	%	15	%	17	%	15	%
Cardinal Health, Inc.	14	%	15	%	14	%	18	%
Amerisource Bergen Corporation	8	%	10	%	8	%	11	%

The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period:

	March 27, 2015		September 26, 2014
McKesson Corporation	32	%	24	%
Cardinal Health, Inc.	18	%	17	%
CuraScript, Inc.	12	%	13	%
Amerisource Bergen Corporation	10	%	13	%

The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales:

	Three Months Ended				Six Months Ended
	March 27, 2015		March 28, 2014		March 27, 2015		March 28, 2014
Acthar (Specialty Brands)	25	%	—	%	28	%	—	%
Optiray™ (CMDS)	6	%	13	%	7	%	13	%